Match Document Document Title
US20140017273 Albumin-Fused Anti-Angiogenesis Peptides  
The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion...
US20120328701 NANOPARTICLE COMPOSITIONS, FORMULATIONS THEREOF, AND USES THEREFOR  
The present invention describes novel nanoparticle compositions, and systems and methods utilizing them for treating disorders and/or conditions. Methods generally involve administering...
US20120263747 Albumin-Fused Anti-Angiogenesis Peptides  
The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit...
US20110020409 Silk Fibroin Hydrogels and Uses Thereof  
The present specification provides for methods for purifying fibroins, purified fibroins, methods of conjugating biological and synthetic molecules to fibroins, fibroins conjugated to such...
US20100166874 Technology for Preparation of Macromolecular Microspheres  
Microspheres are produced by contacting an aqueous solution of a protein or other macromolecule with an organic solvent and a counterion, and chilling the solution. The microspheres are useful for...
US20100092566 Highly concentrated drug particles, formulations, suspensions and uses thereof  
Highly concentrated drug particle formulations are described, wherein the drug comprises between about 25 wt % and 80 wt % of the particle formulation. The particle formulations of the present...
US20100016241 METHODS AND COMPOSITIONS FOR INHIBITING C-MET DIMERIZATION AND ACTIVATION  
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating c-met dimerization and/or binding of ligand to c-met using a c-met...
US20100015144 Methods for dosing an activin-actriia antagonist and monitoring of treated patients  
In certain aspects, the present invention provides methods for dosing a patient with an activin-ActRIIa antagonist and methods for managing patients treated with an activin-ActRIIa anatagonist. In...
US20100008918 Methods for dosing an actriib antagonist and monitoring of treated patients  
In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain...
US20090275519 Therapeutic peptidomimetic macrocycles  
The present invention provides biologically active peptidomimetic macrocycles for the treatment of cell proliferative disorders such as cancer and immunoproliferative disease.
US20090074753 PLATELET-DERIVED GROWTH FACTOR COMPOSITIONS AND METHODS OF USE THEREOF  
A method for promoting growth of bone, periodontium, ligament, or cartilage in a mammal by applying to the bone, periodontium, ligament, or cartilage a composition comprising platelet-derived...
US20070054856 Compositions and methods of using angiopoietin-like 4 protein  
ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to...
US20160368962 Melanocortin Receptor Ligands  
The present invention is directed to compounds according to formula, (R2R3)-A1-c(A2-A3-A4-A5-A6-A7-A8-A9)-A10-R1, and pharmaceutically-acceptable salts thereof that act as ligands for one or more...
US20160347813 GLUCAGON ANALOGUES  
The invention provides glucagon analogue peptides and their use for promoting weight loss or preventing weight gain, and the treatment of obesity or excess body weight and associated conditions....
US20160222060 Immunomodulators  
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases,...
US20160101158 PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME  
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants...
US20160074465 Methods for Treating Hypotension  
The present disclosure relates to the use of angiotensin II in therapeutic methods for the treatment of hypotension, especially catecholamine-resistant hypotension.
US20150125611 SELF-ASSEMBLING PEPTIDE AND PEPTIDE GEL WITH HIGH STRENGTH  
Provide are a peptide gel with practically sufficient mechanical strength and a self-assembling peptide capable of forming the peptide gel. The self-assembling peptide is formed of the following...
US20140364358 Method for Preventing and Treating Hyperpermeability  
A peptide is described, which consists of 7-17 adjacent amino acids and comprises the hexamer TXEXXE, wherein X, X and X can be any natural or non-natural amino acid, wherein the peptide has no...
US20140241993 FLUORESCENT CHLOROTOXIN CONJUGATE AND METHOD FOR INTRA-OPERATIVE VISUALIZATION OF CANCER  
A chlorotoxin conjugate detectable by fluorescence imaging that allows for intra-operative visualization of cancerous tissues, compositions that include the chlorotoxin conjugate, and methods for...
US20140105995 SILK FIBROIN SYSTEMS FOR ANTIBIOTIC DELIVERY  
The present invention provides for silk fibroin-based compositions comprising one or more antibiotic agents for prevention or treatment of microbial contamination, methods of making...
US20140050739 LOCAL COMPLEMENT INHIBITION FOR TREATMENT OF COMPLEMENT-MEDIATED DISORDERS  
The present invention features the local administration of complement inhibitors for treatment of complement-mediated disorders. In certain embodiments the invention features inhibiting activation...
US20140023632 PHARMACEUTICAL FORMULATION  
A pharmaceutical formulation for a PKC modulatory peptide and a transport moiety comprising the aforementioned components and an anti-aggregant.
US20130330380 TOPICAL DRUG DELIVERY USING PHOSPHATIDYLCHOLINE  
The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the...
US20130315980 CYCLODEXTRIN-BASED MATERIALS, COMPOSITIONS AND USES RELATED THERETO  
This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials...
US20130303436 PEPTIDE THERAPEUTICS AND METHODS FOR USING SAME  
Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of GLP-1, and/or naturally or artificially occurring variants...
US20130289621 Drug-Impregnated Encasement  
A drug-impregnated sleeve for encasing a medical implant is provided. In one embodiment, the sleeve may include a body made of a biologically-compatible material that defines an internal cavity...
US20130251674 Non-Aqueous Single Phase Vehicles and Formulations Utilizing Such Vehicles  
The present invention is related to materials and methods for forming polymeric delivery vehicles that reduces risk of oxidative degradation of a carried drug and the resulting compositions.
US20130177611 SILK-BASED DRUG DELIVERY SYSTEM  
The present invention provides for novel sustained release silk-based delivery systems. The invention further provides methods for producing such formulations. In general, a silk fibroin solution...
US20130172234 MULTIMERIC TIE 2 AGONISTS AND USES THEREOF IN STIMULATING ANGIOGENESIS  
The present invention provides a multimeric form of a Tie 2 binding peptide monomer, wherein the multimeric form has Tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates...
US20130143802 FUSION PEPTIDE THERAPEUTIC COMPOSITIONS  
Therapeutic compositions containing fusion proteins (FPs) including elastin-like peptides (ELPs) and peptide active therapeutic agents, and methods of making and using such compositions and fusion...
US20130130968 COMPOUNDS FOR ENZYME INHIBITION  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the...
US20130118491 Delivery of Active Agents  
A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or...
US20130116167 ANTI-MART-1 T CELL RECEPTORS AND RELATED MATERIALS AND METHODS OF USE  
The invention provides a chimeric T cell receptor (TCR) comprising a variable region of a human TCR and a constant region comprising at least an extracellular domain of a constant region of a...
US20130040884 ALBUMIN-BINDING CONJUGATES COMPRISING FATTY-ACID AND PEG  
Novel polypeptide derivatives having protracted profile of action.
US20120315335 SELF-ASSEMBLING NANOPARTICLE DRUG DELIVERY SYSTEM  
A self-assembling nanoparticle drug delivery system for the delivery of drugs including peptides, proteins, nucleic acids or synthetic chemical drugs is provided. The self-assembling nanoparticle...
US20120295848 SUSTAINED-RELEASE COMPOSITION AND PROCESS FOR PRODUCING THE SAME  
Present invention is to provide a sustained-release composition which contains a physiologically active substance in high content even when gelatin is not included, and suppresses its initial...
US20120276126 LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES  
The present invention relates to methods of treating a hyperproliferative disease by administering a composition of lactoferrin alone or in combination with standard anti-cancer therapies.
US20120232005 LIPOPROTEIN COMPLEXES AND MANUFACTURING AND USES THEREOF  
The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The...
US20120230950 Compositions and Methods for Soft Tissue Augmentation  
The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially...
US20120189576 3'-[(2Z)-[1-(3,4-DIMETHYLPHENYL)-1,5-DIHYDRO-3-METHYL-5-OXO-4H-PYRAZOL-4-YLIDENE]HYDRAZINO]-2'-HYDROXY-[1,1'-BIPHENYL]-3-CARBOXYLIC ACID bis-(MONOETHANOLAMINE)  
An improved thrombopoietin mimetic, the bis-(monoethanolamine) salt of 3′-[(2Z)-[1-(3,4-dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo- 4H-pyrazol-4-ylidene]hydrazino]-2′-hydroxy-[1,1′-biphenyl]-3 -car...
US20120101026 Compounds For Enzyme Inhibition  
Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of...
US20120045460 METHODS AND COMPOSITIONS FOR TREATMENT OF GRAFT REJECTION AND PROMOTION OF GRAFT SURVIVAL  
Embodiments of the present invention illustrate methods of treating and preventing transplantation and side effects associated with transplantation. In certain embodiments, compositions and...
US20120014952 COMPLEMENT RECEPTOR 2 TARGETED COMPLEMENT MODULATORS  
Modulation of the complement system represents a therapeutic modality for numerous pathologic conditions associated with complement activation. In a strategy to prepare complement inhibitors that...
US20110236353 ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFOR  
Sequences of novel adeno-associated virus capsids and vectors and host cells containing these sequences are provided. Also described are methods of using such host cells and vectors in production...
US20110206668 METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY  
Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The...
US20110177058 METHODS AND COMPOSITIONS FOR MODULATING HGF/MET  
The invention provides methods and compositions for modulating the HGF/c-met signaling pathway, in particular by regulating binding of HGF β chain to c-met.
US20110123577 Method Of Delivering Stable Topical Drug Compositions  
A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for...
US20110076234 PEPTIDES COMPRISING AN ISODGR MOTIF  
Disclosed herein are peptides which include an isoDGR motif and which selectively inhibit αvβ3 integrin. In some embodiments, the isoDGR motif results from the deamidation of an NGR motif.
US20110046606 Catheter injectable depot compositions and uses thereof  
Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25° C., in an...